Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

central texas community health centers - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5) - for the treatment of conjunctivitis and other superficial ocular infections due to susceptible microorganisms, and as an adjunctive in systemic sulfonamide therapy of trachoma: escherichia coli, staphylococcus aureus, streptococcus pneumoniae, streptococcus (viridans group), haemophilus influenzae, klebsiella species, and enterobacter species. topically applied sulfonamides do not provide adequate coverage against neisseria species, serratia marcescens and pseudomonas aeruginosa . a significant percentage of staphylococcal isolates are completely resistant to sulfa drugs. hypersensitivity to sulfonamides or to any ingredient of the preparation.

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

rpk pharmaceuticals, inc. - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5), prednisolone sodium phosphate (unii: iv021nxa9j) (prednisolone - unii:9phq9y1olm) - sulfacetamide sodium and prednisolone sodium phosphate ophthalmic solution is indicated for corticosteroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain diminution in edema and inflammation. they are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation, or thermal burns or penetration of foreign bodies. the use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. the particular anti-infective drug in this product is active

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

a-s medication solutions - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5) - sulfacetamide sodium ophthalmic solution, usp 10% is indicated for the treatment of conjunctivitis and other superficial ocular infections due to susceptible microorganisms, and as an adjunctive in systemic sulfonamide therapy of trachoma: escherichia coli, staphylococcus aureus, streptococcus pneumoniae, streptococcus (viridans group), haemophilus influenzae, klebsiella species, and enterobacter species. topically applied sulfonamides do not provide adequate coverage against neisseria species, serratia marcescens and pseudomonas aeruginosa . a significant percentage of staphylococcal isolates are completely resistant to sulfa drugs. sulfacetamide sodium ophthalmic solution, usp 10% is contraindicated in individuals who have a hypersensitivity to sulfonamides or to any ingredient of the preparation.

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

rpk pharmaceuticals, inc. - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5) - sulfacetamide sodium ophthalmic solution, usp 10% is indicated for the treatment of conjunctivitis and other superficial ocular infections due to susceptible microorganisms, and as an adjunctive in systemic sulfonamide therapy of trachoma: escherichia coli, staphylococcus aureus, streptococcus pneumoniae, streptococcus (viridans group), haemophilus influenzae, klebsiella species, and enterobacter species. topically applied sulfonamides do not provide adequate coverage against neisseria species, serratia marcescens and pseudomonas aeruginosa . a significant percentage of staphylococcal isolates are completely resistant to sulfa drugs. sulfacetamide sodium ophthalmic solution, usp 10% is contraindicated in individuals who have a hypersensitivity to sulfonamides or to any ingredient of the preparation.

Malta - angļu - Medicines Authority

pharmachemic trading agency company limited - hydroxycarbamide - hard capsule - hydroxycarbamide 500 milligram(s) - antineoplastic agents

Malta - angļu - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - hydroxycarbamide - hard capsule - hydroxycarbamide 500 mg - antineoplastic agents

Kenija - angļu - Pharmacy and Poisons Board

sandoz gmbh kundl biochemiestrasse 106250, austria - hydroxycarbamide - capsule, hard - 500mg - hydroxycarbamide

Kanāda - angļu - Health Canada

pharma stulln inc. - sulfacetamide sodium - solution - 10% - sulfacetamide sodium 10% - antibacterials

Lielbritānija - angļu - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - hydroxycarbamide - oral capsule - 500mg

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

neilmed pharmaceuticals, inc. - carbamide peroxide (unii: 31pz2vau81) (hydrogen peroxide - unii:bbx060an9v) - carbamide peroxide 65 mg in 1 ml - softens ear wax. ear wax removal drops do not use:     * if you have had an allergic reaction to carbamide peroxide.     * if you have ear drainage or discharge, ear pain, irritation or rash in the ear, or are dizzy; consult a doctor     * if you have an injury or perforation (hole) of the eardrum or after ear surgery, unless directed by a doctor     * for more than four consecutive days stop use ad ask a doctor if excessive ear wax remains after use of this product for four consecutive days